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Available online 12 December 2015Hypothermia is potently neuroprotective, but the molecular basis of this effect remains obscure. Changes in neu-
ronal tau protein are of interest, since tau becomes hyperphosphorylated in injury-resistant, hypothermic brains.
Noting inter-species differences in tau isoforms, we have used functional cortical neurons differentiated from
human pluripotent stem cells (hCNs) to interrogate tau modulation during hypothermic preconditioning at
clinically-relevant temperatures. Key tau developmental transitions (phosphorylation status and splicing shift)
are recapitulated during hCN differentiation and subsequently reversed by mild (32 °C) to moderate (28 °C)
cooling — conditions which reduce oxidative and excitotoxic stress-mediated injury in hCNs. Blocking a major
tau kinase decreases hCN tau phosphorylation and abrogates hypothermic neuroprotection, whilst inhibition
of protein phosphatase 2A mimics cooling-induced tau hyperphosphorylation and protects normothermic
hCNs from oxidative stress. These ﬁndings indicate a possible role for phospho-tau in hypothermic precondition-
ing, and suggest that cooling drives human tau towards an earlier ontogenic phenotype whilst increasing neuro-
nal resilience to common neurotoxic insults. This work provides a critical step forward in understanding howwe
might exploit the neuroprotective beneﬁts of cooling without cooling patients.
© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Keywords:
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Human cortical neuron1. Introduction
The lack of neuroprotective treatments for acute and chronic
brain disorders presents a major challenge to modern medicine.
Therapeutic hypothermia is a rare example of a proven neuroprotec-
tive intervention — however, it is only practically useful in restricted
patient groups (Yenari and Han, 2012; Jacobs et al., 2013; Andrews
et al., 2015). Improved mechanistic understanding of neuroprotec-
tive hypothermia could reveal novel molecular targets with which
to exploit the protective effect of cooling in a wider clinical context.
Against this background, a range of experimental systems and stud-
ies of hibernating animals have implicated several pathways that
might mediate hypothermic neuroprotection (Arendt et al., 2003;iences, University of Edinburgh,
chorzek),
. This is an open access article underChip et al., 2011; Yenari and Han, 2012; Rzechorzek et al., 2015). A
potentially important candidate is microtubule-associated protein
tau. Speciﬁcally, reversible hyperphosphorylation of tau in hibernat-
ing, hypothermic and developing brains – brains which are compar-
atively resistant to injury – suggests cold-inducible changes in tau
might contribute to hypothermic neuroprotection (Mawal-Dewan
et al., 1994; Arendt et al., 2003; Planel et al., 2007; Stieler et al.,
2011).
Interspecies differences in cellular and molecular biology have im-
peded translation of neuroprotective strategies frompre-clinicalmodels
to man. With regard to tau, a potentially signiﬁcant species difference
lies in the developmentally-regulated expression of its multiple iso-
forms (Janke et al., 1999). The relative abundance of tau isoforms deter-
mines tau function in health and disease (Trojanowski and Lee, 1995),
therefore this balance might be altered under conditions that inﬂuence
neuronal survival, such as hypothermia.Whilst there is little evidence of
this effect in in vivo models of hypothermic neuroprotection (Stieler
et al., 2011), several core human tau isoforms are absent in the adult ro-
dent brain (Janke et al., 1999). These observations provide a strongthe CC BY license (http://creativecommons.org/licenses/by/4.0/).
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in a physiologically relevant human system.
We recently established an experimental platform of functional
hCNs (Bilican et al., 2014; Livesey et al., 2014) and demonstrated
its value for exploring molecular mechanisms of hypothermic pre-
conditioning (Rzechorzek et al., 2015). Here we show that hCN dif-
ferentiation recapitulates the principal features of early human
cortical tau development which are subsequently reversed by hypo-
thermia, returning tau transcriptionally and post-translationally to
an earlier ontogenic state. Further we conﬁrm that cooling protects
these neurons in an injury- and temperature-speciﬁc manner
(Rzechorzek et al., 2015). Finally we provide evidence that cooling-
induced hCN tau hyperphosphorylation results from a dispropor-
tionate suppression of protein phosphatase 2A (PP2A) relative to
glycogen synthase kinase 3β (GSK3β) (Planel et al., 2007), which is
both necessary and sufﬁcient to protect hCNs from oxidative stress.
These ﬁndings establish a role for PP2A inhibition in hypothermic
preconditioning of human neurons and suggest that phospho-tau
may participate in this neuroprotective effect.2. Materials and Methods
2.1. Differentiation of hCNs
hCNs were differentiated from expanded anterior neural precursors
(aNPCs) as described elsewhere (Bilican et al., 2014; Livesey et al., 2014;
see also SupplementalMaterials andMethods). Brieﬂy, upon removal of
FGF2, aNPCs (passages 17 to 39) were plated in 12 or 24-well plates
(Nunc) at 1 × 105 cells cm−2 onto glass coverslips coated with Poly-L-
Ornithine (1 in 1000, Sigma), Laminin (1 in 100, Sigma), Fibronectin
(10 μg/ml, Sigma) and Reduced growth-factor Matrigel® (1 in 200, BD
Biosciences). Differentiating aNPCs were cultured in default media at
3%O2, 5%CO2, 37 °C. For KCl stimulation experiments aNPCswere differ-
entiated in Matrigel® (1 in 100)-coated 6-well plates at the same
density. Cultures were fed twice weekly until 21 d, after which they
were fed every other day. Periodic testing with a PCR-based detection
kit (Minerva Biolabs) conﬁrmed that both precursor and differentiated
cultures were Mycoplasma-free. For developmental characterization,
samples were harvested at aNPC stage and 14, 28, 42 and 49 d after
plating for differentiation. Electrophysiological characterization of
hCNs is described elsewhere (Bilican et al., 2014; James et al., 2014;
Livesey et al., 2014).2.2. Cooling Paradigm
Triplicate plates for each hCN batch were maintained in normal
differentiation media. Hypothermia was induced at 5 wk when
N90% of cultured cells are differentiated neurons and N95% of these
ﬁre action potentials (Bilican et al., 2014). Identical plates were
separated and incubated at 28, 32 or 37⁰C to simulate ‘moderate
hypothermia’, ‘mild hypothermia’ or ‘normothermia’ respectively
(Rzechorzek et al., 2015). Hypothermic temperatures were selected
to simulate suspended animation at the lower limit of cardiac stabil-
ity and the minimum clinical target temperature for therapeutic hy-
pothermia (Zell and Kurtz, 1985; Yenari and Han, 2012; Andrews
et al., 2015). Thermic period was calibrated with a sentinel culture
plate. Time zero was set when media in the sentinel plate reached
the desired incubation temperature, measured by digital thermome-
ter. Samples for early and late analysis of transcripts were captured
for RNA extraction at 3 and 24 h respectively. At 24 h cells were
ﬁxed for immunocytochemistry and additional samples lifted for
phospho-protein (see Supplemental Materials and Methods). For
media additions during the hypothermic period, solutions were
pre-warmed to the respective temperatures.2.3. Electrophysiology
Whole-cell patch-clamp recordings were made from hCNs using an
Axon Multiclamp 700B ampliﬁer (Molecular Devices, Union City, CA).
Patch electrodes (~4–7MΩ)were ﬁlledwith an internal recording solu-
tion comprising (in mM): K-gluconate 155, MgCl2 2, HEPES 10, Na-
PiCreatine 10, Mg2-ATP 2 and Na3-guanosine triphosphate 0.3, pH 7.3
(300 mOsm). Coverslips containing hCNs were super-fused with an
extracellular solution composed of (in mM) NaCl 152, KCl 2.8,
HEPES 10, CaCl2 2, glucose 10, pH 7.3 (320–330 mOsm) using a
gravity-feed system at room temperature (20–23 °C). The recording
solution was supplemented with glycine (50 μM), picrotoxin
(50 μM), strychnine (20 μM), and tetrodotoxin (300 nM). Recordings
were made at a holding potential of−74 mV (including liquid junc-
tion potential correction). Series resistances (Rs) were generally less
than 25 MΩ.2.4. PP2A Enzyme Activity
PP2A activity was assayed using an Immunoprecipitation Phospha-
tase Assay Kit (Millipore) according to the manufacturer's instructions,
with a few minor adaptations. Brieﬂy, cell pellets from 5 wk old hCNs
were thawed on ice, solubilised in cold phosphate extraction buffer
(20mM Imidazole-HCl (Santa Cruz), 2 mMEDTA, 2mM EGTA, protease
inhibitors and 100 μMPMSF) and sonicated for 10 s. After centrifugation
(2000 ×g for 5 min at 4 °C), supernatants were collected and their
protein concentration measured by BCA assay (Pierce). 100 μg of each
lysate was incubated (constant rocking for 1 h at 4 °C) with an antibody
speciﬁc to the active subunit of PP2A (Anti-PP2A, C subunit, clone 1D6)
and Protein A agarose slurry in pNPP Ser/Thr Assay Buffer. Agarose
beadswere washed several timeswith TBS and Ser/Thr Assay Buffer be-
fore the addition of a Threonine Phosphopeptide (K-R-pT-I-R-R, ﬁnal
concentration 750 μM). Identical samples from each cortical batch
were incubated for 10min on a shaking incubator under one of 4 condi-
tions (28, 32 or 37 °C or at 37 °C in the presence of 100 nM of fostriecin
(CalBiochem)). After brief centrifugation, triplicate aliquots of each
sample were transferred to a 96-well microtitre plate. Malachite
Green Phosphate Detection Solution was added to each well and the
plate incubated at room temperature for 15 min. Absorbance was mea-
sured on a spectrophotometer at 620 nm. Sample readings were com-
pared to a 200–2000 pM Phosphate Standard Curve after subtraction
of the blank (negative control) value. The speciﬁc PP2A activity (pico-
moles of phosphate released min−1 μg−1 protein) was calculated for
each sample and its internal negative control (with fostriecin) so that
this background ‘activity’ relating to residual phosphate levels could
then be subtracted. Hypothermic sample values were then compared
to their respective normothermic controls.2.5. Statistical Analysis
Pairwise correlations were performed by two-tailed Pearson corre-
lation. All remaining analyses were performed using linear mixed
models in Stata SE (Version 9.2, Stata Corp, TX, USA) with random ef-
fects for intercept by batch, and where necessary, with random effects
for coefﬁcient by concentration or time (Aarts et al., 2014). N denotes
the number of individual cell lines used and n describes the number of
independently differentiated batches of hCNs. Unless otherwise stated,
data are presented as standardized point estimates (SPE) + standard-
ized estimated standard error (SESE) after normalizing to control
values. Control values refer to aNPC, normothermia (37 °C) or untreated
cells for differentiation, hypothermia, KCl/FPL stimulation and pharma-
cological studies respectively. In every case, asterisks denote signiﬁ-
cance of the test statistic as follows: *p b 0.05, **p b 0.01, ***p b 0.001,
****p b 0.0005.
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3.1. Tau Development in hCNs
Functional hCNs express an enriched cortical transcript proﬁle
(Espuny-Camacho et al., 2013; Bilican et al., 2014; Livesey et al.,
2014), display axonal-dendritic polarization and exhibit ultrastructural
synaptic morphology (see Fig. S1). However taumodulation – a key fea-
ture of neuronal development– has not previously been explored in this
system. In the adult human brain, six major tau isoforms arise from
alternative splicing of the geneMAPT (Goedert et al., 1989a). These iso-
forms differ by their number of repeated microtubule binding domains;
three repeat (3R) tau predominates during early development, whilst
approximately equal levels of 3R and 4R tau exist in the mature brain
(Goedert et al., 1989b; Goedert and Jakes, 1990). To determinewhether
hCN differentiation reﬂects normal developmental changes in tau, we
examined neurons at serial time points from 1 to 7 wk after plating.
Early tau development was recapitulated at transcript level with signif-
icant increases in total, 3R and 4R tau expression during differentiation
of independent hES and iPS-derived hCNs (Fig. 1A). A shift in 3R:4R ratio
between wk 4 and 7 partially mimicked the transition from human
foetal to adult brain (Fig. 1B). Tau protein was not detected in neural
precursors (Fig. 1C). Dephosphorylation of soluble cell lysates prior to
SDS-PAGE produced a clear shift in electrophoretic mobility and re-
solved the tau signal at wk 4 and 6 into a single band, corresponding
to foetal isoform 3R0N (Goedert et al., 1989b) (Fig. 1C). Immunocyto-
chemistry conﬁrmed a prominent 3R tau expression and an increase
in the proportion of hCNs expressing tau during differentiation
(Fig. 1D–E). Further, it showed a cell soma-restricted expression of pro-
tein detected with a 4R human tau-speciﬁc antibody by wk 4 (Fig. 1D),
which extended further into neuronal processes by wk 7 (Fig. 1F).
Alongside splicing regulation, tau becomes progressively dephos-
phorylated during development, increasing its afﬁnity for microtubules
(Gong et al., 2000). This is attributed to increased expression of PP2A—
the principal tau phosphatase in the human brain (Yu et al., 2009).
Foetal brain tau is thus more highly phosphorylated than adult brain
tau, but both become dephosphorylated in post-mortem samples
due to residual PP2A activity (Brion et al., 1993; Matsuo et al., 1994)
(Fig. 2A–B). Reﬂecting their early developmental state, tau phosphory-
lation (and electrophoretic mobility) in hCNs under basal conditions
was similar to that observed in primary cultures derived from human
foetal cortical samples (Fig. 2B). Tauphosphorylation at several epitopes
decreased betweenwk 4 and 6 of differentiation (Fig. 2C–D), coinciding
with an increase in PP2A mRNA expression (Fig. 2E). Importantly, tau
was absent in negative control samples (primary human and hiPS-
derived astroglia) but was identiﬁed in oligodendroglia (Lopresti et al.,
1995) within primary mixed glial cultures derived from human foetal
ventral telencephalon (Fig. 2F–G). In summary, tau modiﬁcations with
respect to both 3R:4R ratio and phosphorylation during differentiation
of hCNs recapitulate features of early in vivo human cortical tau devel-
opment. In this regard, hCN cultures offer a suitable platform for explor-
ing human tau physiology under hypothermic conditions.
3.2. Cooling Reverts Tau to an Earlier Developmental State
Brain tau protein in rodentmodels becomes increasingly and revers-
ibly phosphorylatedwith decreasing temperature, consistentwith reca-
pitulation of a “foetal-like” state (Mawal-Dewan et al., 1994; Stieler
et al., 2011). To determinewhether hypothermiamodiﬁes tau dynamics
in functional human neurons we evaluated tau isoform transcripts in
wk 5 hCNs following hypothermic incubation for 24 h. An increase in
3R:4R tau ratio was observed with cooling, most notably at 32 °C
(32 °C, P b 0.0005 and 28 °C, P= 0.012, Fig. 3A–D). This shift reﬂected
a signiﬁcant increase in 3R tau transcript at both hypothermic tem-
peratures (P b 0.01) and a reduction in 4R tau transcript at 32 °C
(P=0.009, Fig. 3A–D). Total tau transcript expression and transcriptN-terminal length remained stable across temperatures (Figs. 3B and
S2). Western blot analysis conﬁrmed an increase in 3R tau protein
expression at 28 °C (P= 0.011), alongside a decrease in electropho-
retic mobility, but no detectable change in tau solubility (Figs. 3E and
S2). Quantitative immunolabelling revealed a 35% reduction in 4R
tau-positive cells at 32 °C (Fig. 3F–G, P = 0.017). These results are
consistent with cooling-induced reversal of tau isoform and post-
translational state, without the oligomerization typically assigned
to ‘pathological tau’ (Spillantini and Goedert, 2013).
We further characterized post-translational effects of cooling by
immunocytochemistry and quantitative Western analysis of tau
phosphorylation at the AT8 epitope (pSer202/pThr205). AT8 is heavily
phosphorylated in the foetal and diseased adult human brain, as well
as hypothermic rodent models (Planel et al., 2007). At 24 h we noted
a temperature-dependent increase in AT8 expression with cooling
according to Western analysis (normalized to total tau expression;
32 °C P = 0.004, 28 °C P b 0.0005) and cell counts (32 °C P = 0.008,
28 °C P b 0.001) (Fig. 4A–C). A similar increase in phosphorylation (nor-
malized to total tau expression)was seen at other phospho-tau epitopes
associated with pathological tau (PHF-1 P b 0.05, AT180 P b 0.01, AT270
P b 0.0005, Fig. 4D) including AT100 (see Fig. S3). In hypothermic ro-
dents, a disproportionate inhibition of tau phosphatase activity (relative
to tau kinase activity) is thought to underlie a hypothermic increase in
tau phosphorylation (Planel et al., 2004). In hCNs, no difference was
seen in PP2A-Bγ transcript (not shown) or in protein levels of the active
subunit of PP2A (PP2A-C) with temperature shift (Fig. 4E). To evaluate
phosphatase activity, we immunoprecipitated PP2A-C from wk 5 cul-
tures and measured the ability of this isolate to release phosphate
from a threonine phosphopeptide (K-R-pT-I-R-R) at the 3 temperatures
of interest over a 10 min period. As an additional negative control, a
sample of isolated PP2A-C from each hCN batch was simultaneously in-
cubated at 37 °C in the presence of fostriecin (a selective inhibitor of
PP2A (Walsh et al., 1997)) — the resultant background phosphate
level was subtracted from the test lysates. Both mild and moderate hy-
pothermia produced a N60 % reduction in PP2A-C activity (32 °C P =
0.041, 28 °C P= 0.034, Fig. 4F). Together these ﬁndings reveal that hy-
pothermia induces reversal of key tau ontogenic features and impairs
tau phosphatase activity in human cortical neurons in vitro.
3.3. Hypothermia Reduces Oxidative and Excitotoxic Injury in hCNs
Identical hCN batches were cultured at three different tempera-
tures (28 °C, 32 °C and normothermia (37 °C)) to demonstrate the
neuroprotective effect of hypothermia against oxidative stress. Tem-
perature shift alone did not affect hCN viability or culture purity
(Fig. S4). To avoid a confounding cellular stress by re-warming, we
pre-cooled hCNs for 24 h then maintained them at their respective
temperatures throughout exposure to stressors in minimal medium
(MiM) (Lleonart, 2010; Chip et al., 2011). The combined cooling and
stress paradigm is summarized in Fig. 5A. 24 h treatment with H2O2
produced concentration-dependent injury according tomultiplexed in-
jury analysis (Rzechorzek et al., 2015) and cell death counts (Fig. 5B–E).
Hypothermia was neuroprotective; injury in response to 100 μM H2O2
treatment was reduced by 36% at 32 °C (19.9% versus 31.3% at 37 °C,
P = 0.046) and 78% at 28 °C (6.9% versus 31.3%, P b 0.0005) (Fig. 5B).
Cell death counts reﬂected the injury data (reduction at 32 °C, 14.6%,
P= 0.013, and at 28 °C, 29.2%, P b 0.0005, Fig. 5C).
To determinewhether cooling protected hCNs against another com-
mon neuronal stressor, we examined the effect of hypothermia on glu-
tamate-mediated excitotoxicity (Gupta et al., 2013). Neurons cultured
inMiMwere vulnerable to concentration-dependent glutamate toxicity
(Fig. 6A). Coolingwas again protective; cell injury following exposure to
30 μM glutamate was reduced by 25% at 32 °C and 56% at 28 °C (51.4%
and 29.9% injury respectively versus 68.6% injury at 37 °C, P b 0.0005
for both comparisons). To verify the physiological relevance of this
excitotoxic response, we established that it was abolished at each
Fig. 1.Differentiating hCNs recapitulate early human tau development. (A) q-RT-PCR analysis of total, 3R and 4R tau transcripts from aNPC stage to wk 6 (N=2; n=5; HES1 n=4, IPS1
n=1; 4R tau at 4 wk P=0.005, other increases P b 0.0005). (B) Shift in tau isoform ratio between wk 4 and 7 (N= 1; HES1 n=5; P b 0.0005), partially mimics transition from human
foetal to adult brain (triplicate cDNA synthesised from commercially pooled RNA). Transcript data normalized to geometricmean of 3 differentiation-stable reference targets then present-
ed as SPE+SESE relative to aNPC expression (for hCNs) ormean of triplicates+SEM(for pooled humanbrain). (C)Western blot of soluble tauduringhCNdifferentiation, run by10% SDS-
PAGE with (+) or without (−) prior dephosphorylation with alkaline phosphatase (AP). Blot probed with pan-tau antibody (upper image) recognising all tau isoforms irrespective of
phosphorylation status. Positive control includes recombinant human tau protein ladder (RT) containing 6 human brain tau isoforms. Membrane re-probed with 3R tau-speciﬁc antibody
RD3 (lower image). β-actin= loading control. (D) Fluorescentmicrographs of hCNs (IPS1) at wk 4, co-stained for DAPI, neuronal markers (microtubule-associated protein 2 (MAP2) and
βIII-tubulin) and tau (pan-tau, 3R- or 4R-speciﬁc). Somatic-axonal distribution of 3R and total tau reﬂects developing polarity, scale bar = 10 μm. (E) Quantiﬁcation of hCN protein
expression by immunolabelling, asterisks denote signiﬁcant changes relative to wk 2 post-plating (N= 3; n ≥ 4; HES1 n ≥ 2, IPS1 n ≥ 1, IPS2 n ≥ 1, P b 0.0005). Cell counts presented as
mean + SEM. (F) Fluorescent micrographs of hCNs 53 d post-plating showing more extensive 4R tau staining (scale bar = 10 μm). See also Fig. S1.
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Fig. 2.Phospho-tau expression in differentiating hCNs. (A) Soluble tau expression in humanpost-mortem cortical tissue samples. Upper blot: 3 independent adult control samples (A1, A2, A3
ages 17, 44 and75 yr. respectively)— notemultiple tau isoforms and lack of taumobility shift after AP treatment demonstrating lowphosphorylation status after post-mortem interval (PMI)
(Matsuo et al., 1994). RL= recombinant human tau ladder. Lower blot: 3 independent Alzheimer disease samples (Alz1, Alz2, Alz3 ages 60, 61 and 81 yr. and Braak stages 6, 5 and 6 respec-
tively), note tau ‘smears’ indicating oligomerizationwith reduced solubility compared to control samples. Poor electrophoretic mobility indicates hyperphosphorylated andmultimeric state
that cannot be altered by AP treatment and is relatively unaffected by PMI. (B) Comparison of soluble tau expression in mature hCNs and human foetal cortex. 3 independent foetal cortical
samples (F1, F2, F3 at 14, 15 and 16wk gestation respectively) and primary cultures derived from these samples (C1, C2, C3 respectively) (see SupplementalMaterials andMethods). 7wk=
hCNs at 7 wk post-plating. Note mobility shift between tissue and culture samples, indicating that PMI allows continued dephosphorylation of tissue samples prior to processing. Note that
7wk hCN tau alignswith primary culture tau. Blot probedwith pan-tau antibody that recognises both phosphorylated and dephosphorylated tau. (C) Soluble phospho-tau expression during
hCNdifferentiation. Blot shows total tau in aNPCs andhCNs at various points duringdifferentiation (2, 4 and6wk post-plating) as compared to foetal cortical sample at 19wk gestation, adult
control cortex, andAlzheimerdisease (Alz)cortex.Noteexpression in4wkhCNs isgreater thanat6wkand in foetal andadult samplesbut is similar toAlz. Foetal samplesits at lowermolecularweight than
hCN samples evenwithout AP treatment, indicating lower phosphorylation status due to PMI. (D)Western blots probedwith antibodies speciﬁc for tau phospho-epitopes. Note decrease in signal at each
epitopebetweenwk4and6ofhCNdifferentiation,weaksignal innormal adulthumancortex(age17yr)andprominent signal inAlz-affectedcortex(age60yr., Braakstage6).NoteAT8andAT270signals
are less than PHF-1 in the diseased sample, reﬂecting order in which any remaining soluble tau becomes dephosphorylated during PMI (Matsuo et al., 1994), despite low PP2A expression (see Fig. 4E).
(E) PP2A Bγ transcript changes in hCNs (N= 2; n=5; HES1 n= 4, IPS1 n= 1, P b 0.005) echo human brain development. (F) Confocal image of hPS-derived astrocytes, negative for tau (scale
bar = 10 μm). (G) Fluorescent micrographs of astrocytes (left) and oligodendroglia (right) in mixed primary cultures derived from 19 wk post-mortem foetal ventral telencephalon. Note somatic 3R
tau (RD3) expression in O4-positive oligodendroglia but absence of tau in GFAP-positive astroglia, scale bar= 50 μm.
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(NMDARs), principally composed of GluN1/GluN2B subunits
(Fig. 6A–B). With absolute cell death counts protection was evident at
32 °C (20.5% versus 30.1% death at 37 °C, P = 0.001), but not at 28 °C
(28.8% death, P = 0.654) (Fig. 6C–D). Taken together, these results
conﬁrm that mild-to-moderate hypothermia protects human cortical
neurons from both oxidative and glutamate-mediated injury in vitro.3.4. PP2A Inhibition Increases Tau Phosphorylation and Reduces Oxidative
Injury in Normothermic hCNs
Tau hyperphosphorylation may offer short-term protection by pro-
moting apoptotic escape (Liu et al., 2012). Since hypothermia robustly
increased tau phosphorylation in hCNs, we postulated that this might
contribute to its neuroprotective effect. First we determined whether
147N.M. Rzechorzek et al. / EBioMedicine 3 (2016) 141–154neuroprotection could be achieved by inhibiting PP2A. Fostriecin was
applied to normothermic hCNs for 24 h, afterwhich cellswere immuno-
stained, harvested for protein extraction or subjected to oxidative stress.
Fostriecin treatment produced a visible increase in axonal AT8 immuno-
reactivity, a concentration-dependent increase in phospho-tau signal on
Western blot and a reduction in hCN injury in response to H2O2 (P =
0.008, Fig. 7A–C). Culture at 28 °C predictably reduced oxidative
stress-mediated injury across all H2O2 doses (P b 0.0005), however
the addition of fostriecin conferred no further beneﬁt (P = 0.907,
Fig. 7C). Conversely, treatment with the kinase inhibitor TCS 2002
(highly selective for the major tau kinase GSK3β (Saitoh et al., 2009))
produced a concentration-dependent decrease in phospho-tau signal
as well as a prominent shift in electrophoretic mobility on Western
blot (Fig. 7B). Addition of TCS 2002 increased hCN injury in response
to H2O2 under both normothermic and hypothermic conditions (P =
0.002 and P = 0.001 respectively, Fig. 7D). TCS 2002 abrogated the
protective effect of moderate hypothermia at 50 μM H2O2; there was
no signiﬁcant difference between injury in untreated normothermic
cultures and hypothermic cultures treated with TCS 2002 (P= 0.348).
Importantly, expression of the activated form of GSK3βwas unaffected
by cooling, conﬁrming the availability of this enzyme for TCS 2002 inhi-
bition at 28 °C (Fig. 7E). Finally, immunolabelling of hCNs for activated
caspase-3 and AT8 showed that thesemarkers weremutually exclusive,
suggesting that phospho-tau positive neuronswere resistant to apopto-
sis (Li et al., 2007) (Fig. 7F). In summary, these ﬁndings are consistent
with a rapid, cooling-induced hyperphosphorylation of tau, coupled
with a potent defence of human cortical neurons against acute oxidative
injury. Our results further indicate that this protective effect is saturated
at 28 °C.
4. Discussion
This study establishes an in vitromodel of hypothermic taumodula-
tion in human cortical neurons. hCNs respond robustly to cooling, with
changes in tau at transcript, protein and post-translational levels,
consistent with reversal of ontogenic transitions in tau status observed
during differentiation. Hypothermia also prevents hCN injury in
response to exogenous stressors, operating in a temperature- and
stress-speciﬁcmanner. Finally we show that hypothermic neuroprotec-
tion is impaired at 28 °C and mimicked at 37 °C using compounds that
reciprocallymodify tau phosphorylation. Our results provide further ev-
idence that phospho-taumay participate in a neuroprotective response,
and that our translatable cooling paradigm offers a simple tool with
which to test this hypothesis in future studies.
Temporal analysis of hCN differentiation captured fundamental as-
pects of early human cortical tau development, including a shift in tau
isoform ratio and a parallel decrease in tau phosphorylation. Even at
later time points, hCN tauwasmore phosphorylated than that extracted
from human adult and foetal cortical tissue (Fig. 2C–D). Comparison of
phosphorylation status in post-mortem samples and hCNs is confound-
ed by PMI, during which residual PP2A activity can take effect (MatsuoFig. 3.Hypothermia reverses tau isoform shift in hCNs. (A) q-RT-PCR analysis of transcripts inwk
showing signiﬁcant increase in 3R tau at both hypothermic temperatures (left). Note also a late
ratio (right). Transcript data normalized to geometric mean of 2 temperature-stable reference t
displayed as fold change relative to normothermic control ratio at 3 h. (B)QualitativeRT-PCRprod
from 3 independent batches of hCNs (left to right; HES1 n=2; HES2 n=1) after 24 h culture at
products obtainedwith primers that span tau exons 1 to 5, thus amplifying transcripts of variable
brainwith low expression of 1 N isoforms, and approximately equal expression of 0N and 1N tra
shift on N-terminal length are noted. Lower panel shows products obtained with primers that s
respectively). Note roughly equal expression of 3R and 4R tau in human adult brain and predom
transcript expression at 32 °C, consistentwith q-RT-PCR results. This increase saturates the signa
tau expression is however notable in (C) where similar products from normothermic wk 5 hCN
expression in these hCNs approximates to 8:1, consistent with that predicted from q-RT-PCR re
Pearson correlation illustrates dissociation of relationship between 3R and 4R tau transcripts at
upwardmobility shift of 3R tau in hypothermic cultures. 3R tau solubility was unaffected (3R tau
heterogeneous nuclear ribonucleoprotein (hnRNP)A1 serve as cytosolic and nuclear loading cont
HES1 n= 3, IPS1 n= 1), depicted in ﬂuorescent micrographs in (G), merged images show co-set al., 1994). In support of this, tau phosphorylation was reduced in
foetal human post-mortem cortices relative to primary cultures
derived from these samples (Fig. 2B). Despite a considerable PMI,
tau extracted from adult human pathological samples remained
hyperphosphorylated (Fig. 2A and C–D), likely due to reduced PP2A
expression (Fig. 3E) or shielding of phospho-epitopes within
multimeric insoluble tau species (Fig. 2A). An unresolved challenge
is to derive a protocol that efﬁciently and reproducibly generates
wild-type human neurons with a mature tau proﬁle. As found in
other human in vitro systems (Sposito et al., 2015), our hCNs are lim-
ited with respect to biochemical analysis of tau isoforms, complicat-
ed by sparse availability of 4R tau-speciﬁc antibodies. One possible
explanation for the discrepancy between our immunocytochemical
andbiochemical readouts for 4R tauprotein inhCNs is that this target resided
inarelatively insoluble fraction, ineffectivelyextractedprior toSDS-PAGE.De-
spite these caveats, the data above shows that hCNs can be used to study as-
pects of developing tau physiology in a clinically-relevant context. Indeed, an
immature proﬁlemay be desirable formodelling therapeutic hypothermia—
an intervention most widely used to treat hypoxic ischaemic neonatal en-
cephalopathy (Yenari and Han, 2012; Jacobs et al., 2013). Hypothermia re-
versed the principal features of tau development observed during hCN
differentiation, pushing tau towards an earlier ontogenic state. Tau thus be-
came hyperphosphorylated with a signiﬁcant reduction in PP2A activity at
low temperatures. This hypothermic modulation of PP2A appears to out-
weigh any hypothermic inactivation of tau kinases (Fig. 7E) as described in
other systems (Planel et al., 2004; Bretteville et al., 2012). Accordingly, we
found that TCS 2002 (but not fostriecin) impacted upon hCN injury at
28 °C, suggesting a residual GSK3β (but not PP2A) activity at this tempera-
ture. In addition,we noted a hypothermic shift in tau isoform ratiowith a de-
crease in 4R tau expression at 32 °C. Further work is needed to identify the
mechanism(s) responsible for tau splicing shift in response to cold-stress,
andwhether this requiresassociatedchanges in theexpressionordistribution
of tau splicing regulators.
In agreement with others, we found that short periods of hypother-
mia have negligible effect on basal viability, but reduce cell injury in the
face of oxidative stress (Antonic et al., 2014; Rzechorzek et al., 2015).
Ourmultiplexed injury analysis (Rzechorzek et al., 2015) also addresses
previous limitations including the impact of cell number variability
across treatment conditions (Antonic et al., 2014). Hypothermic protec-
tion of hCNs from glutamate-mediated cell death was temperature-
speciﬁc (Fig. 6C), whereas that from glutamate-induced cellular injury
was temperature-dependent (Fig. 6A). Resolving cytotoxicity and
viability data (Fig. S5) shows that, despite a temperature-dependent
decrease in lactate dehydrogenase (LDH) release, ATP production was
similar at both hypothermic temperatures. Cell death counts were
however lowest at 32 °C. One interpretation is thatmoderate hypother-
mia affected lipid bilayer structure (Lleonart, 2010) thus preventing
LDH release. However, viability may have also been underestimated
if hypothermia affected enzymatic production of ATP. Another con-
founding factor might be residual precursor proliferation at higher tem-
peratures compared to cell cycle arrest at 28 °C (Lleonart, 2010). Our cell5 hCNs (N=3; n=14; HES1 n=7, HES2 n=4, IPS1 n=3) after 24 h temperature shift
decrease in 4R tau expression at 32 °C (middle). At 24 h this produces a shift in tau isoform
argets then to normothermic control at each time point. Note that 3R/4R transcript ratio is
ucts generatedwith tau exon spanning primers (see SupplementalMaterials andMethods)
3 different temperatures, as compared to human foetal and adult brain. Upper panel shows
N-terminal length. Note predominant expression of 0 N transcripts in both hCNs and foetal
nscripts in adult brainwith low expression of 2 N species. No obvious effects of temperature
pan tau exons 9–11, thus amplifying transcripts with or without tau exon 10 (4R or 3R tau
inance of 3R tau species in both hCNs and human foetal brain. There is a clear increase in 3R
l,making it difﬁcult to visualise the low expression of 4R tau in hCNs at any temperature. 4R
s (HES1) were analysed without temperature-shifted cells. Note that the ratio of 3R to 4R
sults in Fig. 1B. β-actin serves as a housekeeping target in both (B) and (C). (D) Two-tailed
32 °C (28 °C P b 0.0005, 32 °C P= 0.012, 37 °C P b 0.0005). (E) Representative blot depicts
found in RIPA-soluble fraction (R) but absent from high detergent fraction (H); β-actin and
rols respectively. (F) Cell counts show reduction in4R tau expression at 32 °C (N=2; n=4;
taining for DAPI and βIII-tubulin, scale bar = 10 μm. See also Fig. S2.
148 N.M. Rzechorzek et al. / EBioMedicine 3 (2016) 141–154
149N.M. Rzechorzek et al. / EBioMedicine 3 (2016) 141–154count data is thus complementary to, but distinct from our multiplexed
injury analysis, which offers an additional, objective assessment of
culture health (Rzechorzek et al., 2015). Overall we have demonstrated
that hypothermia protects human cortical neurons in vitro from
glutamate-mediated excitotoxicity, in addition to oxidative stress
(Rzechorzek et al., 2015) – key components of both acute and chronic
neuronal injury.
The molecular mechanisms underlying hypothermic neuroprotec-
tion are ill-deﬁned, although several pathways are implicated in other
model systems and within the cyclical adaptation of hibernating brains
(Arendt et al., 2003; Stieler et al., 2011; Yenari and Han, 2012; Peretti
et al., 2015; Zhu et al., 2015). Direct effects such as a reduced rate of gen-
eration of oxidative species and changes in glutamate receptor function
may be involved in hypothermic neuroprotection against oxidative and
excitotoxic stress respectively (Dietrich et al., 2009). In addition, tem-
pering either one of these stressors directly may have indirect beneﬁts
with respect to the other. For example, modulation of synaptic activity
can increase antioxidant capacity (Papadia et al., 2008) and hypother-
mia can reduce ischaemia-induced glutamate release (Busto et al.,
1989). Cold-shock proteins are also emerging as critical regulators of
hypothermic neuroprotection (Peretti et al., 2015; Zhu et al., 2015)
and these factors may feature signiﬁcantly in the hypothermic precon-
ditioning of hCNs (Rzechorzek et al., 2015). Of particular relevance to
our current work is that the synaptic plasticity of hibernation has been
linked to modiﬁcation of tau, in a manner that closely resembles hypo-
thermic transitions in hCNs (Arendt et al., 2003). The re-acquisition of a
primitive tau status could offer multiple beneﬁts such as potentiation of
hCN tolerance to glutamate. Interestingly, a negative feedback loop has
been described in which tau phosphorylation responds to NMDAR
activity and subsequently prevents ‘overexcitation’ (Mondragon-
Rodriguez et al., 2012). Our results suggest that tau isoform balance in
particular may inﬂuence the ability of hCNs to withstand excitotoxic
insults. This would argue for isoform-speciﬁc roles of tau in synaptic
homeostasis and would further advocate humanmodelling of neuronal
injury. 4R tau reduction might also be essential when phosphorylation
state is high, minimising available sites for excessive phosphoryla-
tion and subsequent aggregation. Ultimately, reduced 4R tau along-
side increased tau phosphorylation might confer a more plastic
cytoarchitecture — a prerequisite for repair or reorganisation.
Injury was unchanged in the presence of fostriecin under hypother-
mic conditions. This highlights the potency of cooling-induced PP2A
suppression and suggests that tau phosphorylation was saturated at
this temperature. Concurrently, inhibiting tau phosphorylation had
the opposite effect to fostriecin, preventing the protection that would
have otherwise been achieved at 28 °C. It must be noted that both
PP2A and GSK3β have multiple protein targets other than tau that
may have contributed to (or indeed driven) the protective effects
noted in this study. However, emerging evidence suggests that tau
hyperphosphorylation might promote apoptotic escape (Liu et al.,
2012; see also Fig. 7F), pointing to a speciﬁc enrolment of phospho-
tau in hypothermic neuroprotection. We recently reported that hypo-
thermia primes proteostatic pathways in hCNs, thus providing ‘cross-
tolerance’ to multiple stressors (Rzechorzek et al., 2015). The trigger
for this preconditioning response remains to be identiﬁed, but given
its rapid emergence in response to cooling, its association withFig. 4. Hypothermia inhibits PP2A and increases tau phosphorylation in hCNs.(A) Representative
increased phospho-tau (AT8) with hypothermia. β-actin = loading control, for multiplexed imag
(red).Note apparent lowerphosphorylation state of post-mortemsamples (foetal, adult, Alzheimer)
within the insoluble fractionwhichwasnot assessed).Note also that Alzheimer sample has been loa
other lanes. (C)Western blot quantiﬁcation of AT8 expression, normalized to total tau (N=3; n=
n=3, HES2 n=2, IPS1 n=1). Cell count data are presented as mean+ SEM. (D) Immunoblots d
sociated quantiﬁcation (N=3; n=6; HES1 n=4, HES2 n=1, IPS1 n=1). Phospho-tau expres
(N=3;n=6;HES1n=4,HES2n=1, IPS1n=1).Note lackof effect of hypothermia, prominent e
inAlzheimerdisease affected cortex (negative control). (F)Hypothermic reductionof PP2A-C activit
n=4). Enzymeactivitypresentedasmean fold change relative tonormothermic control+SESE, aft
was 469 (SEM 27.7) picomoles μg−1 protein. See also Fig. S3.endoplasmic reticulum stress (Iqbal et al., 2009) and its capacity to elicit
an unfolded protein response (Liu et al., 2012), hyperphosphorylated
tau represents an attractive candidate. Extending our knowledge of
the preconditioning phase is a potentially fruitful avenue for targeting
the earliest stages of neurodegenerative disease, in which the role of
tau remains poorly understood. Based on the data provided above, we
conclude that over a 48 h period of cooling, hyperphosphorylation of
tau was correlated with neuronal protection rather than neuronal
injury.
Historically, increased tau phosphorylation has been associated
with neural demise. Consequently, rodent studies exploring increased
neuroﬁbrillary pathology after exposure to cooling-re-warming
paradigms have linked this pathological risk with hypothermic
hyperphosphorylation of tau (Planel et al., 2009). On the contrary, by
excluding a re-warming phase (and the rebound cellular stress that
might ensue (Lleonart, 2010; Rzechorzek et al., 2015)), our work indi-
cates that real-time tau transitions under hypothermia do not negate
its protective effect andmay promote neuronal survival. In hCNs, tau re-
sponses to cooling extended to alternative splicing ofMAPT, in amanner
that complements the developmental reversal of tau phosphorylation
state. This may be an essential feature of hypothermic tau in human
neurons that simultaneously permits cytoskeletal plasticity whilst
retaining tau solubility. Whilst it is tempting to speculate that cooling
could impart a therapeutically-tractable, ‘neonatal’ plasticity to the
adult brain, the effect of hypothermia on mature human tau isoforms
is currently unknown. It must also be considered that increased plastic-
ity within established networks may be undesirable in terms of cogni-
tive outcome, even if it provides a neuroprotective beneﬁt overall.
Notwithstanding these caveats, our work fundamentally explores the
molecular basis of hypothermic neuroprotection under ‘ideal’ circum-
stances— i.e. those inwhich neuronal temperature can be directlymea-
sured and controlled prior to and during the injury phase without the
confounding effects of rewarming and other practical drawbacks (and
risks) of clinical cooling. This approach not only lends itself to drug dis-
covery (circumventing the need to cool patients), it raises the prospect
of pharmacologically retaining protective factors that might otherwise
be reversed upon rewarming. Manipulation of tau phosphorylation in
the context of both cooling and injury has yielded the clearest evidence
to date that protection of human neurons against oxidative stress is not
impeded by tau hyperphosphorylation in the acute phase. Whether this
would hold in the long term, or indeed whether tau is speciﬁcally con-
tributing to hypothermic neuroprotection is yet to be determined in
our system. Overall, these ﬁndings argue for further study of hypother-
mic preconditioning and context-dependent tau modulation to exploit
their neuroprotective potential.Author Contributions
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and S.C.images of AT8 expression at 3 temperatures, scale bar = 10 μm. (B) Western blot showing
e AT8 and β-actin were imaged in 800 nm channel (green) and total tau in 700 nm channel
due to PMI andbecauseonly soluble proteinwas loaded (mostAT8 signalwouldbe contained
ded at a lower total protein concentration to avoid oversaturation of signal for quantiﬁcationof
6; HES1 n=4, HES2 n=1, IPS1 n=1) and quantiﬁcation by cell count (N=3; n=6; HES1
epicting signiﬁcant increases in tau phosphorylation at 3 other epitopes with cooling and as-
sion was normalized to total tau, then 37⁰C control. (E)Western blot quantiﬁcation of PP2A-C
xpression innormal humancortex (foetal and adult positive controls) and reduced expression
y inhCNs (picomolesphosphate releasedmin−1 μg−1 proteinN=2;n=8;HES1n=4,HES2
er subtractionofbackgroundphosphate;mean residual phosphate in thepresenceof fostriecin
Fig. 5. Hypothermia protects hCNs from oxidative stress-mediated injury. (A) Overview of cooling and stress protocol showing temperature shift for 24 h followed by application of
stressors. After 24 h of stress (total 48 h of hypothermia), multiplexed injury analysis was performed. Immunocytochemistry was used to conﬁrm cell death by counts (100 μM H2O2
and 30 μM glutamate conditions only). (B) Multiplexed injury analysis with dose response curves for H2O2 (N= 2; n= 9; HES1 n= 5, HES2 n= 4). 200 μM H2O2 produced maximal
injury at 37⁰C when compared to positive control (cell lysis with Triton-X). (C) Cell death counts (N=3; n=8; HES1 n=5, HES2 n=2, IPS1 n= 1). Note that incubation temperature
had no effect on cell death when neurons were incubated in MiM alone. (D) Representative ﬂuorescent micrographs of hCNs after 24 h incubation with 100 μMH2O2, scale bar = 10 μm.
Cells were co-stained for nuclear (DAPI), neuronal (βIII-tubulin) and astrocytic (GFAP) markers. Note small number of GFAP-positive cells at each temperature, scant GFAP-positive pro-
cesses and absence of neuronal processes at 37⁰C suggesting resistance of a few astrocytes to this concentration ofH2O2. (E) Phase images of hCNs taken before and after incubation for 24 h
with 100 μM H2O2 at temperatures indicated, scale bar = 20 μm. Injury data presented as point estimates (PE) ± estimated standard error (ESE) relative to normothermic control. Cell
count data presented as mean + SEM. See also Figs. S4 and S5.
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Fig. 6.Mild hypothermia protects hCNs fromNMDAR-dependent glutamate excitotoxicity. (A) Dose response curves for glutamate injury in presence of speciﬁc (ifenprodil) and non-speciﬁc
(D(−)-2-Amino-5-phosphonopentanoic acid, D-APV) NMDAR blockers (N= 2; n= 9; HES1 n= 5, HES2 n= 4). The ‘zero treatment’ control data from Fig. 5B was used to normalize re-
sponses to exogenous glutamate. Notemaximal injury not achievedwith 100 μMglutamate, suggesting someglutamate tolerance at baseline. Note shift of each injury curvedownwardswith
decreasing temperature and shift upwards at 32 °C in presence of 1 μMglutamate and ifenprodil (P=0.001), consistentwith protective effect of low exogenous glutamate (Hardingham and
Bading, 2010). Both blockers prevented the toxic effect of high glutamate, conﬁrming that excitotoxicitywas GluN2B-mediated at each temperature (P b 0.0005). Injury data are presented as
PE ± ESE relative to normothermic control. (B) Representative current trace (left) of 5 wk-old hCNs in response to NMDA (100 μM) in presence of glycine (50 μM) at a holding potential of
−74 mV. Application of 3 μM ifenprodil (a GluN2B-speciﬁc inhibitor) produces approximately 80% block of NMDA-mediated current, conﬁrming it is largely mediated by GluN1/GluN2B-
containing NMDARs. Mean % NMDA receptor block ± SEM was equivalent across all cell lines investigated (right, HES1 n= 14 cells from 4 independent batches, HES2 n= 4 cells from 1
batch, IPS1 n=4 cells from 1 batch). (C) Cell death counts in response to 30 μMglutamate presented as mean+ SEM (N=3; n=8; HES1 n=5, HES2 n=2, IPS1 n=1) and conﬁrmed
a 31.8% reduction in cell death at 32 °C (P= 0.001). (D) Representative images of hCNs after 24 h incubation with 30 μM glutamate
,
scale bar = 10 μm. See also Figs. S4 and S5.
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Fig. 7.Hypothermic neuroprotection ismediated by PP2A inhibition. (A) Fostriecin treatment of normothermic hCNs increases tau phosphorylation as shownby enhancedAT8 immunolabelling (100 nM
fostriecin, scale bar= 50 μm) and (B) concentration-dependent increase in AT270 and pan-tau signals onWestern blot with decreased electrophoretic mobility. Tau kinase (GSK3β) inhibitor TCS 2002
decreases tauphosphorylation ina concentration-dependentmanner andat high concentrations resolves theprotein into itsdephosphorylated isoformsof lowermolecularweight (upperblot). Commonly
used GSK3 inhibitors have an effect on normothermic tau (lower blot), comparable to that of TCS 2002 (Saitoh et al., 2009). AR-014418 concentrations are in μM, those for LiCl are in mM. The pan-tau
antibody recognises phosphorylated and non-phosphorylated tau, GAPDH= loading control. (C) Fostriecin reduces H2O2-mediated injury (N=3; n=6; HES1 n=3, HES2 n=1, IPS1 n=1) but
has no effect on injury when hCNs are incubated at 28⁰C. (D) TCS 2002 increases H2O2-mediated injury at 37⁰C and 28⁰C (N=3; n=4; HES1 n=1, HES2 n=1, IPS1 n=2). Note that y-axis has
been logged for both (C) and (D). (E) Quantiﬁcation byWestern blot of total, activated (phosphorylated at Y216) and deactivated (phosphorylated at S9) GSK3β expression at 3 temperatures. For total
and pS9, N=3; n=4; HES1, n= 2; HES2, n=1, IPS1, n=1; for pY216, N=3; n=6; HES1, n= 4; HES2, n=1, IPS1, n=1. Total GSK3β expression was normalized to GAPDH, phosphorylated
GSK3βwas normalized to total GSK3β. GSK3β phosphorylates tau and is recognised as an apoptosis inducer (Meares et al., 2011). Note increase in the deactivated form at 28 °C (P= 0.018).
(F)FluorescentmicrographsofhypothermichCNs showingmutuallyexclusive stainingofphospho-tau (AT8)andapoptoticmarkeractivatedcaspase-3. Cellswere co-stained forDAPI andneuronalmarker
βIII-tubulin, scale bar= 10 μm.
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